Moderna Reveals its Coronavirus Vaccine Has had Promising Results

Biotech company Moderna has revealed this week that its coronavirus vaccine has shown promising results in a small trial of elderly people.

Moderna tested the vaccine on 10 adults ranging from the age of 56 to 70 and 10 other patients ranging from the age of 71 and older. Each participant received two 100 microgram doses of the vaccine at 28 days apart.

The company said that the patients produced neutralizing antibodies, which researchers believe are necessary to build immunity to the virus, and T-cells. Additionally, the antibodies that were produced were higher than those seen in people who have recovered from Covid-19.

Moderna is charging between $32 and $37 per dose for its coronavirus vaccine for some customers, under cheaper “pandemic pricing.”

President Donald Trump announced recently the U.S. government would purchase 100 million doses of Moderna’s vaccine in a deal worth $1.53 billion. The U.S. has already invested $955 million in Moderna’s vaccine development, bringing its total investment up to nearly $2.5 billion.

In July the company started a phase three trial testing how safe and effective it is on 30,000 people with results expected as early as October. Moderna also said it anticipates completing enrollment for its phase three trial next month.

Disclaimer: We have no position in Moderna Inc. (NASDAQ: MRNA) and have not been compensated for this article.